Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (November 15th Preview)
-
FDA rejection of ivonescimab in narrow NSCLC setting
The FDA has rejected Summit Therapeutics and Akeso’s PD-1 x VEGF antibody ivonescimab for approval in a narrow non-small cell lung cancer setting, citing lack of overall survival benefit. In an FDA letter to the companies, reviewers said the treatment’s disease-control effect was not enough to support a positive benefit-risk profile without longer-life data. The decision is a regulatory setback for Summit, which is developing the drug outside China, though the outcome was described as not entirely unexpected by observers. The rejection further underscores how survival endpoints continue to shape checkpoint-adjacent approvals, even when progression endpoints look favorable. No details were provided in the dataset beyond the FDA’s rationale that slowed worsening did not translate into a statistically and clinically meaningful survival advantage.
-
Long-term outcomes for BRAF-altered CNS tumors
Long-term follow-up from the phase 1/2a PLX120-03 study indicates durable responses with plixorafenib (PLX8394/FORE8394) in BRAF V600-altered primary CNS tumors. Data presented for a prespecified efficacy subgroup showed an 80% objective response rate in BRAF V600E high-grade gliomas and 50% in low-grade/glioma/neuronal tumors. Progression-free survival rates were reported at 56% at 12 months and 33% at 24 months. Investigators also reported no evidence of cumulative adverse effects with prolonged dosing, with some patients remaining on therapy for years, and additional responses when post-progression treatment included other MAPK inhibitors. The study is positioned as single-agent evidence for plixorafenib’s approach to inhibit BRAF V600 monomers and disrupt mutant dimers to avoid paradoxical pathway activation.
-
Early PET-based response signals for IDH-mutant glioma
Interim multicenter European data presented for the IDH-mutant glioma program show serial amino-acid PET can detect early metabolic responses to vorasidenib sooner than structural MRI. In patients assessed with PET Response Assessment in Neuro-Oncology 1.0, partial responses occurred in 29% versus 6% by RANO 2.0. The median time to response was 4 months by PET RANO 1.0 compared with 8 months by RANO 2.0, with metabolic tumor volume change driving early classification. Stable disease rates were also higher in PET RANO 1.0 assessments (62% vs 74%), while progressive disease percentages remained similar. Researchers at Erasmus MC in Rotterdam emphasized the clinical constraint that MRI tumor volume can change slowly under therapy, motivating PET-based earlier readouts.
-
Micronutrient/nutrition pipeline signal: bromotherapy and acute responses
A bedside-to-bench signal links early nutritional intervention strategies to downstream clinical or mechanistic outcomes. In one report, N-acetylcysteine restored impaired store-operated calcium entry and nitric oxide production in endothelial cells from calcific aortic valve stenosis patients, pointing to oxidative stress-linked dysfunction. In another study thread, animal and lab models explore Nrf2/GPX4 and ferroptosis-related mechanisms as nutrition-adjacent biology—such as ginsenoside Rg1’s lab evidence for reducing fatty liver injury by activating the Nrf2/GPX4 axis and limiting ferroptosis. Together, the dataset highlights how redox biology and nutrient-linked compounds are still being used to generate translational hypotheses for cardiometabolic and vascular diseases, even without direct late-stage clinical validation in the provided materials.
-
Solid tumor immunotherapy science: TROP2 ADCs deliver PFS gains
Comparative analysis of phase III ASCENT-03 and TROPION-Breast02 trial cohorts suggests first-line TROP2-targeted antibody–drug conjugates improve progression-free survival compared with standard chemotherapy in metastatic triple-negative breast cancer patients ineligible for immunotherapy. The dataset frames consistent PFS benefit across the immunotherapy-ineligible subgroup comparisons. The analysis reinforces the continuing shift toward tumor-antigen selection in ADC development, where clinical benefit appears to depend on target engagement and patient eligibility criteria rather than solely on histology. No additional survival metrics or safety rates were included in the provided content.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.